AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-28 - Roadshow - Day 1

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

150.3 USD

Average target price

161.4 USD

Spread / Average Target

+7.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.07%	233B
NOVO NORDISK A/S	+25.76%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
NOVARTIS AG	+5.33%	201B
ROCHE HOLDING AG	-9.98%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B
SANOFI	+0.62%	123B

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:08:19 2024-04-26 am EDT			5-day change	1st Jan Change
11,949 ^GBX	-0.64%		+9.49%	+13.07%

01:56pm	ASTRAZENECA : Gets a Buy rating from Barclays	ZD
01:43pm	Barclays Raises AstraZeneca PT, Affirms at Overweight	MT

ASTRAZENECA : Gets a Buy rating from Barclays	07:56am	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	07:43am	MT
Peel Hunt cuts ConvaTec to 'reduce'	04:34am	AN
THE FTSE 100 is on a roll	04:23am
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade	Apr. 25
FTSE 100 shakes off red-hot US inflation gauge	Apr. 25	AN
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
ASTRAZENECA : UBS maintains a Sell rating	Apr. 25	ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	Apr. 25	MT
The specter of stagflation rears its ugly head again	Apr. 25
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	Apr. 25	DP
Sector Update: Health Care	Apr. 25	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	Apr. 25	MT
ASTRAZENECA : Jefferies sticks Neutral	Apr. 25	ZD
ASTRAZENECA : JP Morgan remains its Buy rating	Apr. 25	ZD
FTSE 100 hits high on offer for Anglo American	Apr. 25	AN
Transcript : AstraZeneca PLC, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
AstraZeneca Q1 Core Earnings, Revenue Increase -- Shares Jump Premarket	Apr. 25	MT
ANALYST RECOMMENDATIONS : Meta Platforms, UPS, Boeing, Chipotle, Dell Technologies...	Apr. 25
AstraZeneca Earnings, Sales Rise, Beating Forecasts -- Update	Apr. 25	DJ